Navigating the complexities of both nanoparticle-based therapeutics and oral solid dose (OSD) formulations requires a sharp focus on scalability, bioavailability, and manufacturing stability. From engineering lipid nanoparticles (LNPs) for targeted drug delivery to optimizing bioavailability and modified-release profiles in OSD products, developers must balance intricate formulation chemistry with commercial viability.
Bridging these distinct disciplines allows drug developers to overcome solubility hurdles, protect fragile active ingredients, and establish efficient tech transfer pathways. Specialized techniques, advanced analytical characterization, and tailored processing methods help resolve persistent technical bottlenecks at every stage of development.
Discover new strategies for refining nanoparticle performance and elevating OSD manufacturing workflows by exploring the presentations featured in this edition of the Outsourced Pharma Capabilities Update (OPCU). Watch below to gain actionable insights for your next development program.
Recent Sessions Available On-Demand
Cell Therapy & Cell Line Development – July 2026
ADCs And Microbial Development & Manufacturing – July 2026
Cell Line Development – August 2026
Upcoming OPCU Topics & Times
ADCs | 9/11/2026, AM Session
AI Innovation in Drug Development & Manufacturing | 9/29/2026, AM Session
Viral Vectors | 9/29/2026, PM Session
mRNA | 9/30/2026, AM Session
Packaging, Labeling, & Logistics Services | 9/30/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.
